Alternative Concept: Ketamine Infusion Company Targets Alcohol Dependence
Solvonis Therapeutics, a biotech company based in the UK, is making waves in the healthcare industry with its focus on developing potential treatments for alcohol abuse, PTSD, and depression. One of its key assets, SVN-002, is an experimental treatment for alcohol addiction, targeting the significant US market for alcohol addiction treatments.
A Large and Untapped Market
The US market for alcohol addiction treatments is vast, with approximately 22 million Americans struggling with alcohol use disorder (AUD) [1]. This is in contrast to Johnson & Johnson’s Spravato, which addresses a smaller market of a couple of million Americans with severe depression, yet generates over $1 billion in annual revenues, with potential peak revenues around $5 billion [1].
Leveraging Existing Data for Faster Approval
SVN-002 is an experimental esketamine-based treatment, chemically similar to Spravato. Solvonis aims to leverage Spravato's existing data via the FDA’s 505(b)(2) pathway to streamline approval and reimbursement processes, potentially accelerating market entry and cost efficiency [1].
Growth Prospects and Competitive Advantage
With the large untreated or inadequately treated population and high relapse rates in current AUD treatments, SVN-002 could capture substantial market share if efficacy and safety translate from current trials. The chemical similarity to Spravato may allow for leveraging existing clinical and commercial frameworks, possibly resulting in faster regulatory approval and adoption under the same reimbursement codes [1].
Potential Revenue Opportunities
While Spravato is already a blockbuster, these figures are for a smaller patient population. SVN-002’s market is much larger, suggesting potentially higher peak revenue if successfully commercialized, assuming similar pricing and adoption rates [1].
Clinical Trials and Regulatory Approval
SVN-002 is preparing for Phase 2b clinical trials targeting moderate to severe AUD in the US [2][3]. The success of these trials and subsequent regulatory approval will determine the market realization of SVN-002.
In addition to SVN-002, Solvonis' lead drug is SNV-001, an experimental treatment for severe AUD. The company has also hired Pharma Ventures, a specialist in partnership and alliances, to shop SNV-001. The UK Department of Health is co-funding the trial for SNV-001. Early trial results for SNV-001 have been encouraging, with 50% fewer heavy drinking days compared to placebo and 86% of participants staying off alcohol for six months [1].
Solvonis has four programs, one in phase III, and the company is planning to seek a mixed-full approval in both the UK and EU for SNV-001 [1]. Conversations regarding a potential licensing agreement between Solvonis and a third party are also taking place [1].
Dennis Purcell, Solvonis' chair, has first-hand experience in negotiations with big pharma due to his role in IGI's $1.9 billion deal with AbbVie [1]. This experience could prove invaluable in securing partnerships and agreements for Solvonis' assets.
Affiliate links in this article may earn commissions for This is Money. DIY investing platforms mentioned include AJ Bell, Hargreaves Lansdown, interactive investor, InvestEngine, and Trading 212.
Value inflection points for companies like Solvonis often come at the end of clinical studies, such as phase II or III. Investors will be watching these developments closely.
[1] Source: Singers Research Note [2] Source: Solvonis Therapeutics Press Release [3] Source: Solvonis Therapeutics Investor Presentation
